Michael W. Bonney
CIK: 0001219016
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Jun 29, 2026AUTL
Autolus Therapeutics plc
Award(A)DirectShare Option (Right to Buy)
47.5K shares- - Jun 29, 2026AUTL
Autolus Therapeutics plc
Award(A)DirectRestricted Share Units
31.7K shares- - Jun 29, 2026IMUX
IMMUNIC, INC.
Award(A)DirectStock Option
100K shares- - Aug 18, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Exercise(M)Direct11.3K shares at avg. $70.20$790K - Aug 18, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct11.3K shares at avg. $450.00$5.1M - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct431 shares at avg. $271.68$117K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct660 shares at avg. $273.16$180K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct882 shares at avg. $273.75$241K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.3K shares at avg. $277.16$350K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $278.01$344K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct432 shares at avg. $280.03$121K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct372 shares at avg. $281.10$105K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct802 shares at avg. $282.03$226K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.7K shares at avg. $282.81$489K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct1.6K shares at avg. $283.83$459K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct301 shares at avg. $275.63$83K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Exercise(M)Direct11.3K shares at avg. $131.21$1.5M - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct549 shares at avg. $267.14$147K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct729 shares at avg. $268.56$196K - May 15, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Sale(S)Direct245 shares at avg. $269.79$66K - May 8, 2025ALNY
ALNYLAM PHARMACEUTICALS, INC.
Award(A)Direct775 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 29, 2026 |  AUTL Autolus Therapeutics plc | Award(A) Share Option (Right to Buy) | 47,500 | - | - | Direct |
| Jun 29, 2026 | AUTL Autolus Therapeutics plc | Award(A) Restricted Share Units | 31,667 | - | - | Direct |
| Jun 29, 2026 |  IMUX IMMUNIC, INC. | Award(A) Stock Option | 100,000 | - | - | Direct |
| Aug 18, 2025 |  ALNY ALNYLAM PHARMACEUTICALS, INC. | Exercise(M) | 11,250 | $70.20 | $789,750 | Direct |
| Aug 18, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 11,250 | $450.00 | $5,062,500 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 431 | $271.68 | $117,094 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 660 | $273.16 | $180,286 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 882 | $273.75 | $241,448 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,263 | $277.16 | $350,053 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,239 | $278.01 | $344,454 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 432 | $280.03 | $120,973 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 372 | $281.10 | $104,569 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 802 | $282.03 | $226,188 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,728 | $282.81 | $488,696 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 1,617 | $283.83 | $458,953 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 301 | $275.63 | $82,965 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Exercise(M) | 11,250 | $131.21 | $1,476,113 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 549 | $267.14 | $146,660 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 729 | $268.56 | $195,780 | Direct |
| May 15, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Sale(S) | 245 | $269.79 | $66,099 | Direct |
| May 8, 2025 | ALNY ALNYLAM PHARMACEUTICALS, INC. | Award(A) | 775 | - | - | Direct |
1-21 of 21 transactions
About BONNEY MICHAEL W
BONNEY MICHAEL W (SEC CIK 0001219016) files insider reports with the SEC as Director of Autolus Therapeutics plc (AUTL), Director of IMMUNIC, INC. (IMUX) and Director of ALNYLAM PHARMACEUTICALS, INC. (ALNY).
Signal8 holds 7 ownership filings by BONNEY MICHAEL W (2 Form 3, 5 Form 4), filed between May 12, 2025 and Jul 1, 2026. Those filings report 21 transactions, from May 8, 2025 to Jun 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on BONNEY MICHAEL W's filings is in LONDON.
Recent filings by BONNEY MICHAEL W
- Jun 29, 2026: Grants or awards of AUTL derivative securities (2 lines, Form 4, code A).
- Jun 29, 2026: Grant or award of IMUX derivative securities (Form 4, code A).
- Aug 18, 2025: Option exercise of ALNY shares (Form 4, code M).
- Aug 18, 2025: Open-market sale of ALNY shares (Form 4, code S).
- May 15, 2025: Open-market sales of ALNY shares (11 lines, Form 4, code S).
Other insiders filing for Autolus Therapeutics plc (AUTL)
- Piccina Cintia, U.S. CCO & Country Gen Manager
- YOUNG WILLIAM D, Director
- Rao Madduri Ravin, Director
- Richardson Ryan, Director
- Leiderman Elisabeth, Director
- Iannone Robert, Director